

**SUPERIOR COURT**  
(Class Action)

CANADA  
PROVINCE OF QUEBEC  
DISTRICT OF MONTREAL

N<sup>o</sup>: 500-06-000831-160

DATE: September 24, 2018

---

BY: **THE HONOURABLE MR. JUSTICE PIERRE-C. GAGNON, J.S.C.**

---

**STEVEN SCHEER**  
Class Applicant

vs.

**BRISTOL-MYERS SQUIBB CANADA CO.**  
and  
**OTSUKA CANADA PHARMACEUTICAL INC.**  
and  
**LUNDBECK CANADA INC.**  
Defendants

---

**JUDGMENT ON PARTIAL DISCONTINUANCE**

---

[1] On December 12, 2016, the Class Applicant filed an Application to Authorize the Bringing of a Class Action & to Appoint the Petitioner as Representative Plaintiff (the "AforA") on behalf of the following class:

"All persons residing in Canada who were prescribed and have ingested and/or injected the drug(s), ABILIFY® and/or ABILIFY MAINTENA® (aripiprazole) and their successors, assigns, family members, and dependants, or any other group to be determined by the Court;

Alternatively (or as a subclass)

All persons residing in Quebec who were prescribed and have ingested and/or injected the drug(s), ABILIFY® and/or ABILIFY MAINTENA® (aripiprazole) and their successors, assigns, family members, and dependants, or any other group to be determined by the Court;";

[2] The Class Applicant named the following 3 entities as Respondents in the AforA:

- I. Bristol-Myers Squibb Canada Co. ("Bristol-Myers")
- II. Otsuka Canada Pharmaceutical Inc. ("Otsuka")
- III. Lundbeck Canada Inc. ("Lundbeck")

[3] The AforA alleges that Bristol-Myers and Otsuka are the co-sponsors for ABILIFY in Canada (see paras. 8 to 10 of the AforA) and that Otsuka and Lundbeck are the co-sponsors for ABILIFY MAINTENA in Canada;

[4] On July 16, 2018, the Class Applicant filed an application for a partial discontinuance seeking permission to discontinue the present legal proceedings as against Respondent Lundbeck (Art. 585 C.C.P.);

[5] On September 24, 2018, the above-mentioned Application was heard by the Court;

[6] The reasons alleged in the above-mentioned Application to support the partial discontinuance are the following:

(a) ABILIFY MAINTENA was on the market for only 19 months before the product monograph warnings included pathological gambling as a potential side effect of ingesting and/or injecting ABILIFY MAINTENA (see paras. 27, 28 & 68 of the AforA)<sup>1</sup>;

(b) ABILIFY MAINTENA is only indicated for the more serious illness of schizophrenia (and not also for bipolar disorder and as an adjunctive treatment of major depressive disorder (MDD)).<sup>2</sup> Due to the characteristics of the disease, schizophrenics are not as readily able to engage in compulsive conduct as those afflicted with bipolar disorder and/or MDD;

(c) ABILIFY MAINTENA is only indicated for individuals with stabilized schizophrenia, meaning, that atypical antipsychotics have already been tolerated (as observed by a physician);

(d) The similar allegations that have been made in the U.S. proceedings (MDL No. 2734 – *In Re: Abilify (Aripiprazole) Products Liability Litigation*) do not specifically included ABILIFY MAINTENA;

(e) Of the 1,331 Class Members that inputted their information on the dedicated CLG webpage, only 3 referred to ABILIFY MAINTENA;

(f) There will be no prejudice to those Class Members that may have taken ABILIFY MAINTENA in any case;

---

<sup>1</sup> ABILIFY MAINTENA was launched in Canada on February 12, 2014 and the inclusion of pathological gambling as a potential side effect of ingesting and/or injecting ABILIFY MAINTENA on the product monograph was on September 15, 2015.

<sup>2</sup> See Exhibits 50 and 51 to the AforA.

[7] SEEING the above-mentioned Application, as well as, the Exhibits in support thereof produced in the Court record;

[8] HEARING the representations made by the Class Applicant's attorneys;

[9] GIVEN the consent by the Respondent Lundbeck to the discontinuance without legal costs;

[10] GIVEN that the Class Applicant's attorneys undertake to place a notice on the Central Registry of Class Actions, on the website www.clg.org, and to email all persons who contacted Consumer Law Group to express interest in the present action;

[11] CONSIDERING that the Court finds the partial discontinuance to be in the interest of justice.

[12] **FOR THESE REASONS, THE COURT:**

[13] **GRANTS** the present Application;

[14] **ORDERS** the Class Applicant to file his act of discontinuance no later than the 10<sup>th</sup> day after the date of this judgment;

[15] **APPROVES** the text of the public notice to putative members, as follows:

<b>Version française :</b>	<b>English version:</b>
<p data-bbox="256 1150 799 1331"><u>AVIS DE DÉSISTEMENT PARTIEL D'UNE ACTION COLLECTIVE</u> (relativement au médicament ABILIFY MAINTENA et envers Lundbeck Canada inc. seulement)</p> <p data-bbox="245 1402 810 1730">1. SOYEZ AVISÉ que par jugement du 24 septembre 2018, la Cour supérieure a autorisé le Demandeur du Groupe à se désister de la demande d'autorisation d'une action collective relativement au médicament ABILIFY MAINTENA et à l'égard de la Défenderesse Lundbeck Canada inc. seulement;</p> <p data-bbox="245 1768 810 1940">2. La demande d'autorisation d'une action collective se poursuit relativement au médicament ABILIFY et à l'égard des autres Défenderesses identifiées aux actes de procédure.</p>	<p data-bbox="873 1150 1360 1251"><u>NOTICE OF PARTIAL DISCONTINUANCE OF A CLASS ACTION</u> (with respect to the drug ABILIFY MAINTENA and with regard to Lundbeck Canada Inc. only)</p> <p data-bbox="829 1402 1398 1688">1. BE AWARE that by judgment dated September 24, 2018, the Superior Court has authorized the Class Applicant to discontinue his application to authorize a class action, with respect to the drug ABILIFY MAINTENA and with regard to Defendant Lundbeck Canada Inc. only;</p> <p data-bbox="829 1768 1398 1940">2. The application to authorize a class action continues with respect the drug ABILIFY and with regard to the other Defendants identified in the proceedings.</p>

- [16] **ORDERS** that said public notice be published in bilingual format:
- (a) on the Class Actions Registry;
  - (b) on the website [www.clg.org](http://www.clg.org) for a duration of at least 120 consecutive days;
- [17] **ORDERS** that copy of said public notice be sent by email to every person having expressed to Class Applicant's counsel of their interest in the present action;
- [18] **WITHOUT LEGAL COSTS.**

  
\_\_\_\_\_  
PIERRE-C. GAGNON, J.S.C.

Me Andrea Grass  
CONSUMER LAW GROUP INC.  
Attorneys for the Class Applicant

Me Michel Gagné  
Me Samuel Lepage  
MCCARTHY TÉTRAULT S.E.N.C.R.L., S.R.L.  
Attorneys for Respondent LUNDBECK CANADA INC.

Me Robert J. Torralbo  
Me Ariane Bisailon  
BLAKE, CASSELS & GRAYDON LLP  
Attorneys for Respondent BRISTOL-MYERS SQUIBB CANADA CO.

Me Frédéric Wilson  
Me Marianne Ignacz  
NORTON ROSE FULBRIGHT CANADA S.E.N.C.R.L., S.R.L.  
Attorneys for Respondent OTSUKA CANADA PHARMACEUTICAL INC.